Deepak Sahasrabudhe
| Title | Professor |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Medicine |
|---|
| Address | University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester NY 14642
|
|---|
|
|
|
| Title | Professor |
|---|
| Institution | University of Rochester Medical Center |
|---|
| Department | Cancer Center |
|---|
|
|
|---|
| Title | Professor |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Urology |
|---|
|
|
|---|
|
Deepak Sahasrabudhe is a Professor of Medicine in the Division of Hematology/Oncology at the James P. Wilmot Cancer Center at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Dr. Sahasrabudhe received his training at Albany Medical Center Hospital in Albany, New York and the University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Dr. Sahasrabudhe is a key teaching faculty member in the Hematology/Oncology Fellowship Program. He has mentored several fellows over the last 17 years.
Dr. Sahasrabudhe's clinical research interest is in urologic malignancies. He also sees patients with melanomas and sarcomas.
Dr. Sahasrabudhe is a member of many national professional organizations including the American College of Physicians, the American Association for Cancer Research, and the American Society of Clinical Oncology.
-
Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR. Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc. 2012 Mar; 87(3):240-6.
-
Scosyrev E, Messing EM, van Wijngaarden E, Peterson DR, Sahasrabudhe D, Golijanin D, Fisher SG. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer. 2012 Jan 1; 118(1):72-81.
-
Dhakal S, Corbin KS, Milano MT, Philip A, Sahasrabudhe D, Jones C, Constine LS. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys. 2012 Feb 1; 82(2):940-5.
-
Corbin K, Fisher S, Sahasrabudhe D, Pandya K, Brasacchio R, Constine LS. Five tumors over six years in eighth decade of life. Cancer Invest. 2008 Jul; 26(6):634-7.
-
Bylund KC, Giampoli E, Singh D, Doerr T, Sahasrabudhe D, Liesveld J, Constine LS. Soft tissue sarcoma in the setting of chronic cutaneous graft versus host disease after allogenic bone marrow transplantation. Cancer Invest. 2008 Jul; 26(6):638-41.
-
Evans EE, Henn AD, Jonason A, Paris MJ, Schiffhauer LM, Borrello MA, Smith ES, Sahasrabudhe DM, Zauderer M. C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer. Mol Cancer Ther. 2006 Nov; 5(11):2919-30.
-
Coppage M, Belanger T, Zauderer M, Sahasrabudhe D. In vitro generation of tumor specific T cells that recognize a shared antigen of AML: molecular characterization of TCR genes. Leuk Res. 2007 Feb; 31(2):195-202.
-
Wagmiller JA, Griggs JJ, Dick AW, Sahasrabudhe DM. Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs. J Oncol Pract. 2006 Mar; 2(2):57-66.
-
Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer. 2005 May 15; 103(10):2035-41.
-
Shunyakov L, Ryan CK, Sahasrabudhe DM, Khorana AA. The influence of host response on colorectal cancer prognosis. Clin Colorectal Cancer. 2004 May; 4(1):38-45.
-
Pandya KJ, Thummala AR, Griggs JJ, Rosenblatt JD, Sahasrabudhe DM, Guttuso TJ, Morrow GR, Roscoe JA. Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast Cancer Res Treat. 2004 Jan; 83(1):87-9.
-
Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, Marquis D, Rosell K, Whiteside T, Phillippe S, Acres B, Slos P, Squiban P, Ross M, Kendra K. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther. 2003 Apr; 10(4):251-9.
-
Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003 Feb 15; 97(4):960-8.
-
Smith ES, Mandokhot A, Evans EE, Mueller L, Borrello MA, Sahasrabudhe DM, Zauderer M. Lethality-based selection of recombinant genes in mammalian cells: application to identifying tumor antigens. Nat Med. 2001 Aug; 7(8):967-72.
-
Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, Ryan CK, Sahasrabudhe DM. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Am J Hematol. 2000 Oct; 65(2):171-3.
-
Woodlock TJ, Sahasrabudhe DM, Marquis DM, Greene D, Pandya KJ, McCune CS. Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. J Immunother. 1999 May; 22(3):251-9.
-
Bennett JM, Sahasrabudhe DM, Hall WJ. Medical oncology and geriatric medicine: is it time for fellowship integration? Cancer. 1997 Oct 1; 80(7):1351-3.
-
Sahasrabudhe DM, Dusel JC. Effect of murine interferon alpha/beta on tumour-induced suppressor function. Cancer Immunol Immunother. 1994 Dec; 39(6):360-6.
-
Sahasrabudhe DM, Burstyn D, Dusel JC, Hibner BL, Collins JL, Zauderer M. Shared T cell-defined antigens on independently derived tumors. J Immunol. 1993 Dec 1; 151(11):6302-10.
-
DeCross AJ, Sahasrabudhe DM. Paraneoplastic Raynaud's phenomenon. Am J Med. 1992 May; 92(5):571-2.
-
Sahasrabudhe DM, Dusel J, Jedlika S. Suppression of delayed type hypersensitivity by desferoxamine. J Immunother (1991). 1991 Apr; 10(2):112-9.
-
McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother. 1990; 32(1):62-6.
-
Sahasrabudhe DM. Inhibition of suppressor T lymphocytes by murine interferon beta. J Exp Med. 1987 Nov 1; 166(5):1573-8.
-
Sahasrabudhe DM, McCune CS, O'Donnell RW, Henshaw EC. Inhibition of suppressor T lymphocytes (Ts) by cimetidine. J Immunol. 1987 May 1; 138(9):2760-3.
-
McCune CS, Henshaw EC, Marquis DM, Sahasrabudhe D, Leary J, O'Donnell RW. Human hybrid tumor cells: observations on their production and clinical effects. J Biol Response Mod. 1987 Apr; 6(2):130-40.
-
Sahasrabudhe DM, deKernion JB, Pontes JE, Ryan DM, O'Donnell RW, Marquis DM, Mudholkar GS, McCune CS. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Mod. 1986 Dec; 5(6):581-94.
-
Capizzi RL, Yang JL, Cheng E, Bjornsson T, Sahasrabudhe D, Tan RS, Cheng YC. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol. 1983 Dec; 1(12):763-71.
-
Sahasrabudhe DM, Parker JC. Decreasing M spike with increasing tumor burden in multiple myeloma. Arch Intern Med. 1981 Aug; 141(9):1152-3.
|
Sahasrabudhe's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
